Morgan Stanley
RCEL icon

Morgan Stanley’s Avita Medical RCEL Stock Holding History

Morgan Stanley’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$828K Buy
200,462
+42,841
+27% +$185K ﹤0.01% 5297
2026
Q1 		$583K Buy
157,621
+7,906
+5% +$33.2K ﹤0.01% 5414
2025
Q4 		$517K Buy
149,715
+52,473
+54% +$209K ﹤0.01% 5498
2025
Q3 		$497K Sell
97,242
-124,951
-56% -$652K ﹤0.01% 5501
2025
Q2 		$1.18M Buy
222,193
+134,180
+152% +$976K ﹤0.01% 5018
2025
Q1 		$716K Buy
88,013
+3,097
+4% +$28.9K ﹤0.01% 5163
2024
Q4 		$1.09M Sell
84,916
-12,497
-13% -$147K ﹤0.01% 5044
2024
Q3 		$1.04M Sell
97,413
-11,219
-10% -$105K ﹤0.01% 5021
2024
Q2 		$860K Buy
108,632
+68,816
+173% +$655K ﹤0.01% 5051
2024
Q1 		$638K Sell
39,816
-22,482
-36% -$364K ﹤0.01% 5201
2023
Q4 		$855K Sell
62,298
-96,314
-61% -$1.1M ﹤0.01% 5007
2023
Q3 		$2.32M Buy
158,612
+122,565
+340% +$2.07M ﹤0.01% 4291
2023
Q2 		$613K Sell
36,047
-20,674
-36% -$303K ﹤0.01% 5116
2023
Q1 		$792K Buy
56,721
+38,863
+218% +$413K ﹤0.01% 4993
2022
Q4 		$118K Sell
17,858
-12,591
-41% -$75.5K ﹤0.01% 5907
2022
Q3 		$161K Sell
30,449
-37,077
-55% -$229K ﹤0.01% 5830
2022
Q2 		$320K Buy
67,526
+32,654
+94% +$202K ﹤0.01% 5647
2022
Q1 		$296K Buy
34,872
+2,014
+6% +$18.6K ﹤0.01% 5704
2021
Q4 		$393K Buy
32,858
+4,282
+15% +$65.3K ﹤0.01% 5691
2021
Q3 		$506K Sell
28,576
-9,811
-26% -$185K ﹤0.01% 5492
2021
Q2 		$788K Buy
38,387
+24,407
+175% +$481K ﹤0.01% 5224
2021
Q1 		$277K Buy
13,980
+553
+4% +$12.9K ﹤0.01% 5472
2020
Q4 		$249K Sell
13,427
-230
-2% -$5.04K ﹤0.01% 5481
2020
Q3 		$344K Sell
13,657
-1,155
-8% -$28.8K ﹤0.01% 4830
2020
Q2 		$452K Sell
14,812
-560
-4% -$17.1K ﹤0.01% 4651
2020
Q1 		$477K Sell
15,372
-788
-5% -$32.6K ﹤0.01% 4398
2019
Q4 		$735K Buy
+16,160
New +$671K ﹤0.01% 4718

Other funds holding RCEL

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Morgan Stanley's RCEL Position: Q2 2026 in Review

Morgan Stanley increased its Avita Medical (RCEL) stake by 27% in Q2 2026, buying an estimated $185K and bringing the position to 200,462 shares worth $828K. The position accounts for ﹤0.01% of the portfolio, ranked #5297.

Morgan Stanley first reported a position in RCEL in Q4 2019 and has held it in 27 quarters since. The position peaked at $2.32M in Q3 2023. 73 funds tracked by Wall St. Rank hold RCEL as of Q2 2026.

  • Morgan Stanley held 200,462 shares of Avita Medical worth $828K as of Q2 2026.
  • Morgan Stanley bought 42,841 Avita Medical shares in Q2 2026, an estimated $185K.
  • Avita Medical made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5297 holding.
  • Morgan Stanley first reported a position in Avita Medical in Q4 2019 and has held it in 27 quarters since.
  • Morgan Stanley's Avita Medical position peaked at $2.32M in Q3 2023.
  • 73 funds tracked by Wall St. Rank held Avita Medical as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.